Literature DB >> 1370198

Abnormalities in the regulation of vasopressin and corticotropin releasing factor secretion in obsessive-compulsive disorder.

M Altemus1, T Pigott, K T Kalogeras, M Demitrack, B Dubbert, D L Murphy, P W Gold.   

Abstract

In light of prior data that the central administration of vasopressin in animals is associated with abnormal persistence of behaviors acquired under aversive conditioning, we studied the secretion of arginine vasopressin into the cerebrospinal fluid and plasma in patients with obsessive-compulsive disorder and controls. Patients with obsessive-compulsive disorder had significantly elevated basal levels of arginine vasopressin in the cerebrospinal fluid and significantly increased secretion of arginine vasopressin into the plasma in response to hypertonic saline administration. Moreover, seven of 12 patients with obsessive-compulsive disorder showed a loss of the normal linear relationship between plasma arginine vasopressin level and osmolality. In addition, cerebrospinal fluid corticotropin releasing hormone, which has synergistic effects with arginine vasopressin centrally and at the pituitary gland, was also significantly elevated in patients with obsessive-compulsive disorder compared with controls.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1370198     DOI: 10.1001/archpsyc.1992.01820010009002

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  23 in total

1.  Central serotonin transporter levels are associated with stress hormone response and anxiety.

Authors:  Matthias Reimold; Astrid Knobel; Michael A Rapp; Anil Batra; Klaus Wiedemann; Andreas Ströhle; Anke Zimmer; Peter Schönknecht; Michael N Smolka; Daniel R Weinberger; David Goldman; Hans-Jürgen Machulla; Roland Bares; Andreas Heinz
Journal:  Psychopharmacology (Berl)       Date:  2010-06-29       Impact factor: 4.530

Review 2.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

Review 3.  Role of corticotropin releasing factor in anxiety disorders: a translational research perspective.

Authors:  Victoria B Risbrough; Murray B Stein
Journal:  Horm Behav       Date:  2006-07-25       Impact factor: 3.587

Review 4.  Childhood stressful events, HPA axis and anxiety disorders.

Authors:  Carlo Faravelli; Carolina Lo Sauro; Lucia Godini; Lorenzo Lelli; Laura Benni; Francesco Pietrini; Lisa Lazzeretti; Gabriela Alina Talamba; Giulia Fioravanti; Valdo Ricca
Journal:  World J Psychiatry       Date:  2012-02-22

Review 5.  Aetiopathogenesis and pathophysiology of bulimia nervosa: biological bases and implications for treatment.

Authors:  F Brambilla
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

6.  Antiaggressive activity of central oxytocin in male rats.

Authors:  Federica Calcagnoli; Sietse F de Boer; Monika Althaus; Johan A den Boer; Jaap M Koolhaas
Journal:  Psychopharmacology (Berl)       Date:  2013-04-28       Impact factor: 4.530

7.  Brain functional connectivity during induced sadness in patients with obsessive-compulsive disorder.

Authors:  Leonardo F Fontenelle; Ben J Harrison; Jesus Pujol; Christopher G Davey; Alex Fornito; Emre Bora; Christos Pantelis; Murat Yücel
Journal:  J Psychiatry Neurosci       Date:  2012-07       Impact factor: 6.186

8.  Obsessive-compulsive symptoms during the postpartum period. A prospective cohort.

Authors:  Emily S Miller; Christine Chu; Jacqueline Gollan; Dana R Gossett
Journal:  J Reprod Med       Date:  2013 Mar-Apr       Impact factor: 0.142

Review 9.  Innovative approaches for the treatment of depression: targeting the HPA axis.

Authors:  Fiona Thomson; Mark Craighead
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

10.  Dysregulation of neurosteroids in obsessive compulsive disorder.

Authors:  K L Bigos; M M Folan; M R Jones; G L Haas; F J Kroboth; P D Kroboth
Journal:  J Psychiatr Res       Date:  2008-06-02       Impact factor: 4.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.